| Literature DB >> 33233700 |
Maliana El Aamri1, Ghita Yammouri1, Hasna Mohammadi1, Aziz Amine1, Hafsa Korri-Youssoufi2.
Abstract
Cancer is the second most fatal disease in the world and an early diagnosis is important for a successful treatment. Thus, it is necessary to develop fast, sensitive, simple, and inexpensive analytical tools for cancer biomarker detection. MicroRNA (miRNA) is an RNA cancer biomarker where the expression level in body fluid is strongly correlated to cancer. Various biosensors involving the detection of miRNA for cancer diagnosis were developed. The present review offers a comprehensive overview of the recent developments in electrochemical biosensor for miRNA cancer marker detection from 2015 to 2020. The review focuses on the approaches to direct miRNA detection based on the electrochemical signal. It includes a RedOx-labeled probe with different designs, RedOx DNA-intercalating agents, various kinds of RedOx catalysts used to produce a signal response, and finally a free RedOx indicator. Furthermore, the advantages and drawbacks of these approaches are highlighted.Entities:
Keywords: RedOx indicator; cancer biomarker; catalysts; electrochemical biosensor; microRNA
Mesh:
Substances:
Year: 2020 PMID: 33233700 PMCID: PMC7699780 DOI: 10.3390/bios10110186
Source DB: PubMed Journal: Biosensors (Basel) ISSN: 2079-6374
Biomarkers associated with the diagnosis and prognosis of cancer.
| Cancer | Biomarkers | Reference |
|---|---|---|
| Breast | BRCA1, BRCA2, MUC1, CEA, CA 15-3, CA 27, CA29, EGFR, EpCAM, HER2; | [ |
| Prostate | PSA, Sarcosine; | [ |
| Brain | MDM2; | [ |
| Pancreas | CA 19-9, PAM4; | [ |
| Gastric/Stomach | CA72-4, CA19-9, CEA, IL-6; | [ |
| Liver | AFP, DCP, GP73; | [ |
| Ovarian | CA 125 (MUC-16), CEA, Claudin-4; | [ |
| Lung | ANXA2, CEA, Chromogranin A, CA 19-9, CYFRA 21-1 (CA-19 fragment), NSE, SCC, SAA1, HER1; | [ |
| Neck | MGMT gene | [ |
Abbreviations: BRCA1, breast cancer 1 gene; BRCA2, breast cancer 2 gene; MUC1, mucin1; CEA, carcinoembryonic antigen; CA, cancer antigen; EGFR, epidermal growth factor receptor; EpCAM, epithelial cell adhesion molecule; HER, human epidermal growth factor receptor; miR, micro-RNA; PSA, prostate-specific antigen; PAP, prostatic acidic phosphatase; MDM2, murine double minute 2; AFP, α-1-fetoprotein; DCP, des-γ-carboxyprothrombin; GP73, golgi protein 73; ANXA2, annexin A2; NSE, neuron-specific enolase; SCC, squamous cell carcinoma antigen; SAA1, serum amyloid A1; P53, protein suppressor gene; MGMT, o6-methylguanine DNA methyltransferase.
Scheme 1Number of publications in the field of micro-RNAs and cancer in the period between 2010 and 2020 (www.scopus.com, analyzed by years) (consulted 25 October 2020) (Keywords: micro-RNAs, cancer).
Figure 1Different architecture of electrochemical biosensors based on labeled probe with RedOx molecules before and after hybridization. (A) Basic design; (B) elimination of labeled probe sequence; (C) the use of secondary probe labeled with RedOx molecule; (D) the use of two-probe labeled sequence, (a) before and (b) after hybridization.
Figure 2Architecture of electrochemical biosensor based on destroying the adsorption of the labeled probe after hybridization step on the electrode surface (a) before and (b) after hybridization.
Figure 3Example of the biosensor with an electrochemical response based on “signal ON”, (A) detection approach using DNA circle for simultaneous detection of miRNA (reproduced with permission from the publisher [60]; (B) scheme of the biosensor design using (a) stand displacement reaction to generates protector output (b) catalytic hairpin assembly to generates H1/H2 duplex output and (c) electrochemical signal generation procedure (reproduced with permission of Royal Society of Chemistry) [61].
Figure 4Example of biosensor obtained with two DNA label with two RedOx markers; (A) standard design reproduced from [68] with permission of publisher, (B) same approach using amplification strategy reproduced with permission of the publisher from [63].
Figure 5Architecture of electrochemical biosensor based on a RedOx molecule labeled probe via a linker molecule (a) before and (b) after hybridization.
Current sensitive electrochemical biosensors using electroactive species-labeled probe sequence miRNA detection.
| miRNA | labeled RedOx Molecule | Platform | Signal Amplification | Tech | Linear Range | LOD | Real-Samples Application | Ref |
|---|---|---|---|---|---|---|---|---|
| miRNA-141 | MB | AuE | SDR | SWV | 0.1 fM–0.2 pM | 23 aM | Human bladder cancer T24 cells | [ |
| - | MB | GCE/PDDA/AuNPs | DSN | SWV | 100 aM–1 nM | 30 aM | human serum samples | [ |
| miRNA-21 | MB | GCE/CNNS/AuNPs | DSN | SWV | 10 fM–1 nM | 2.9 fM | Spiked human serum | [ |
| MiRNA-21 | MB | PtE/AuNFs | MB/barcode AuNPs | DPV | 500 aM–50 pM | 135 aM | spiked human serum | [ |
| miRNA 21 | Fc | AuE | SWCNTs | DPV | 100 pM–3.5 fM | 0.01 fM | Human serum | [ |
| miRNA-155 | Fc | GCE/Mo2C/AuNPs | CHA | DPV | 0.1 fM–1.0 nM | 0.033 fM | Spiked human serum | [ |
| miRNA-21 | Fc | GCE/Mo2C/NCS | SDR | Amperometric | 1.0 fM–1.0 nM | 0.34 fM | Spiked human serum | [ |
| miRNA-21 | AgNPs | GCE/GO | - | LSV | 100 fM–1 nM | 60 fM | serum samples from breast cancer patients | [ |
| miRNA-155 | AgNPs | AuE | SDR and nicking endonuclease | LSV | 1 fM–1 pM | 70 aM | HeLa cells, A549, human renal cubularepithelial | [ |
| Hsa-miR-17-5p | AgNPs | AuE | AuNPs | LSV | 100 aM–0.1 nM | 2 aM | HUVEC, HK-2, HeLa, MCF-7 cells | [ |
| - | AgNCs | AuE | pDNA-AgDNCs@DNA/AgNCs | DPV | 1 fM–1 nM | 0.38 fM | spiked human serum | [ |
| miRNA-21 | AgNPs | AuE | SDR | SWV | 200 pM–1 fM | 0.4 fM | Blood sample | [ |
| miRNA-155 | PEIAgNPs | AuE | - | CV | 200 zM–2 pM | 20 zM | cancerous humann serum | [ |
| miRNA-21 | Thi | GCE/AuNPs | MWCNTs | DPV | 0.1–12000 pM | 0.032 pM | spiked human serum | [ |
| miRNA-155 | Thi | 3D N-doped rGO/AuNPs | AuAgNR | DPV | 10 pM–100 µM | 1 pM | Spiked serum samples | [ |
| miRNA-21 | TB | GCE/DpAu | - | SWV | 1 fM–2 nM | 0.3 fM | MCF-7, human breast cancer cell line | [ |
| miRNA-21 | Pd NPs | GCE/GO | Pd/NPs-DNALNR and CHA | DPV | 1 fM–50 pM | 63.1 aM | Spiked human serum | [ |
| miRNA-21 | Cd | GCE/Au-RGO | TPSs Ru(NH3)63+ | SWV | 1.0 aM–10.0 pM | 0.76 aM | spiked human serum | [ |
| miRNA | CdTe/QDs | AuE | CESA | DPV | 5 aM–5 fM | 1.2 aM | Spiked human serum | [ |
| miRNA-21 | MB and Fc | AuE | - | SWV | 5 fM–0.1 nM | 1.1 fM | MCF-7 and HeLa | [ |
| miRNA-16 | MB and Fc | AuE | - | SWV | 0.1 pM–100 nM | 16 fM | MCF-7 cells | [ |
| miRNA-21 | MB and Fc | GCE/PLLy | LNA/structure“Y”shape | DPV | 10–70 fM | 2.3 fM | MCF-7 cells | [ |
| let-7a | MB and Fc | NS-grafted ITO | - | DPV | 80 aM–300 fM | 25 aM | Spiked human serum | [ |
| miRNA-21 | MB and Fc | AuE | - | DPV | 0.1–100.0 fM | 67 aM | breast cancer cell line MCF-7 | [ |
| miRNA 21 | Fc | AuE/AuNPs | - | DPV | 100 pM to 1 fM | 0.36 fM | serum | [ |
| - | CdSNPs | GCE | AuNPS and DSN | ASV | 1 fM–100 pM | 0.48 fM | HeLa | [ |
| miRNA-21 and miRNA-155 | MB and Fc | SPCE | Fe3O4@Au@HHCR | SWV | 5 fM–2 nM | 1.5 fM | Spiked human serum | [ |
| miRNA-21 and miRNA-155 | MB and Fc | AuE | - | SWV | 10 fM–5 nM | 2.49 fM | HeLa, MCF-7 and MDA-MB-231 cells | [ |
| miRNA-21 and miRNA-141 | Au ion and Ag ion | GCE/Neutravidin | - | SSWV | 0.5−1000 pM | 0.3 pM | Spiked Serum Sample | [ |
| miRNA-21 and miRNA-141 | MB and Fc | SPGE/MXene/AuNPs | - | DPV | 500 aM–50 nM | 204 aM | human plasma cancer patients | [ |
| miRNA-1246 and miRNA-4521 | Pb (II) and Cd (II) | GCE/AuNPs | PbS@ZIF-8 CdS@ZIF-8 | DPV | 1 fM–1 mM | 0.19 fM | spiked human blood | [ |
Abbreviations: Au-disk microE, gold-disk microelectrode; MB, methylene blue; TCEP, tris(2-carboxyethyl) phosphine hydrochloride; SWV, square wave voltammetry; AuNPs, gold nanoparticles; DPV, differential pulse voltammetry; AuE, gold electrode; AgNPs, silver nanoparticles; LSV, linear sweep voltammetry; CdTe QDs, CdTe quantum dots; CESA, cyclic enzymatic signal amplification; 3-QD@DNA NC, triple-CdTe quantum dot-labeled DNA nanocomposites; GCE, glassy carbone electrode; HCR, hybridization chain reaction; Mo2CNSs, molybdenum carbide nanosheets; Fc, ferrocene; Thio, thionine; CHA, catalytic hairpin assembly; GNF@Pt, gold nanoflower/platinum electrode; SDR, strand displacement reaction; DepAu; HeLa, human cervical cancer cell line; MCF-7, human breast adenocarcinoma cell line; SPCE, screen-printed carbone electrode; Strep, streptavidine; HUVEC, human umbilical vein endothelial cells; HK-2, human renal cubular epithelial cell; A549, human pulmonary carcinoma cell line; LNA, locked nucleic acid; NCS, N-carboxymethyl chitosan; PLLy, polylysine; NS, 1-naphthalenesulfonate; ZIF-8, Zeolitic imidazolate framework, Pb, Plomb sulfide, CdS, Cadmium sulfide; CdS NPs, cadmium sulfide nanoparticules; DSN, duplex-specific nuclease; ASV, anodic stripping voltammetry; AuAgNR, gold and silver nanorod; rGO, reduced graphene oxide; Pd NPs, palladium nanoparticules; SSWV, stripping square-wave voltammetry; SPGE, screen-printed gold electrode; PDDA, polydiallyldimethylammonium chloride; CNNS, carbon nitride nanosheet; SWCNTs, single-walled carbon nanotubes; MDA-MB-231: human breast cancer cells; MWCNTs, multi-walled carbon nanotubes; AgNCs, silver nanoclosters; RGO, polyethylenimine-grafted graphene; Ru(NH3)63+, hexaamine ruthenium(III); PtE, platinum electrode; TB, toluidine blue; AuNFs, gold nanoflowers; TPSs, titanium phosphate spheres; PEIAgNPs, polyethyleneimine-silver nanoparticles, HHCR, hyperbranched hybridization chain reaction.
Figure 6Principle of electrochemical biosensor based on different types of catalysts before (a) and after hybridization (b) with micro-RNA, (A) enzyme, (B) chemical catalyst, (C) DNAzyme.
Figure 7A sandwich-type electrochemical biosensing platform for microRNA-21 detection using carbon sphere-MoS2 and catalyzed hairpin assembly for signal amplification (reproduced with permission from the publisher) [109].
Figure 8Schematic display of the amperometric integrated sensor developed for miRNA determination using a specific thiolated RNA probe, a direct RNA/miRNA hybridization assay and p19 viral protein as detector bioreceptor further labeled with anti-MBP-HRP (reproduced with permission from the publisher) [117].
Figure 9Principle of the enzyme catalytic amplification of miRNA-155 detection with graphene quantum dot-based electrochemical biosensor (reproduced with permission from the publisher) [118].
Figure 10Schematic illustration of the fabrication of the biosensor: (A) preparation procedure of S1-AuNPs@Cu-MOFs; (B) the detection principle for glucose and the strategy of signal amplification; (C) structure of H1, target, and H2 (reproduced with permission from the publisher) [120].
Figure 11(A) DNA-functionalized AuNP based hybridization chain reaction, (B) Schematic illustration of miRNA biosensor using layered nanostructure of oxidized single-walled carbon nanotubes and nanodiamonds by hybridization chain reaction (reproduced with permission from the publisher) [129].
Current sensitive electrochemical biosensors using catalysts.
| MicroRNA | Catalysts/Amplification Agents | Platform | Substrat or Reagent | Technique | Linear Range | LOD | Real-Samples Application | References |
|---|---|---|---|---|---|---|---|---|
| miRNA-21 | ALP/DNA-linked GO–AuNPs | GCE/MgO/AuNPs | AAP | DPV | 0.1–100 fM | 50 aM | Spiked human serum | [ |
| miRNA -21 | ALP/HCR | AuE | α-NP | SWV | 1 fM–100 pM | 0.56 fM | Spiked HEK293T cells | [ |
| miRNA-21 | ALP/CHA-WO3-Gr | GCE/WO3-Gr/AuNPs | Ascorbic acid 2-phosphate | DPV | 0.1 fM–100 pM | 0.05 fM | Serum samples from breast cancer patients | [ |
| miRNA -21 | HRP/AuNPs | AuE | H2O2 | Amperometry | 0.1 fM–100 pM | 43.3 aM | A549 tumor cells | [ |
| miRNA-155 | ALP/CHA | GCE/MWCNTs PtNPs | Phosphate ion | DPV | 10 fM–1 nM | 1.64 fM | Cervical cancer cells and human breast cancer cell lines | [ |
| miRNA-155 | ALP/- | SCPE/Fe3O4 | AAP | DPV | 0.6–9 ng/mL | 29 pM | Spiked human serum | [ |
| miRNA-21 | HRP/- | SCPE/Fe3O4 | H2O2 | Amperometry | 1.0–100 pM | 10 aM | MCF-7 cells | [ |
| miRNA -155 | HRP/GQDs | AuE | TMB | Amperometry | 1fM–00 pM | 0.14 fM | Spiked human serum | [ |
| miRNA-21, let-7a & miRNA-31 | HRP/HCR | SPCE/Fe3O4 | H2O2 | Amperometry | 1.2–100 pM | 0.66 pM | MCF-7 cells | [ |
| miRNA-21 | HRP/- | SPCE/Fe3O4 | H2O2 | Amperometry | 3.0 to 100 nM | 0.91 nM | MCF-7 cells | [ |
| miRNA-21 | Copper (II) complex/HCR | GCME/Fe3O4 | TMB | DPV | 100 aM–100 nM | 33 aM | human serum samples from breast cancer | [ |
| miRNA-155 | Cu-MOFs/AuNPs | Au-PWE | Glucose | DPV | 1 fM–10 nM | 0.35 fM | Spiked human serum | [ |
| miRNA-21 | Sn-In2O3/- | AuE | O2 | DPV | 5 pM–0.5 fM | 1.92 fM | A549 and HeLa cell lines | [ |
| miRNA-21 | G-quadruplex−hemin/- | AuE | H2O2 | DPV | 0.1 fM–0.1 pM | 0.04 fM | Human serum samples from breast cancer | [ |
| miRNA-21 | G-quadruplex−hemin/HCR | AuE/SWCNT-ox/NDs/SWCNTs-ox/AuNPs | H2O2 | DPV | 10 fM–1.0 nM | 1.95 fM | Spiked human serum | [ |
Abbreviations: GCE, glassy carbone electrode; NDs, nanodiamonds; MB, magnetic beads; SWCNTs, single-walled carbon nanotubes; α-NP, α-naphtyl phosphate; AAP, ascorbic acid 2-phosphate; WO3-Gr, tungsten oxide-graphene composites; AA, ascorbic acid; ALP, alkaline phosphatase; CHA, catalytic hairpin assembly; DPV, differential pulse voltammetry; MgO, magnesium oxide; GO, graphene oxide, AuNPs, gold nanoparticles; AuE, gold electrode; HCR, hybridization chain reaction; SWV, square wave voltammetry; HEK293T cells, from human embryonic kidney 293T cells; SPCE, screen-printed carbon electrodes; H2O2, hydrogen peroxide; HRP, horseradish peroxidase; MCF-7 cells, human breast adenocarcinoma cell line; TMB, 3,3′,5,5′-tetramethylbenzidine; GQDs, graphene quantum dots; A549, human lung carcinoma cells; HeLa cells, human cervical cancer cells; Au-PWE, gold-paper working electrode; Cu-MOFs, copper-based metal–organic frameworks; G-quadruplex−hemin, Guanine-quadruplex−hemin; MDA-MB-231, human breast cancer cell lines, Sn-In2O3, tin-doped indium oxide particles. MWCNTs, multi-walled carbon nanotube, platinum nanoparticles, PtNPs; magnetic nanoparticles, Fe3O4.
Figure 12Principal of electrochemical biosensor based on RedOx intercalating agent before (a) and after hybridization (b) with micro-RNA, (A) direct intercalation, and (B) intercalation via the template.
Figure 13Example of biosensors using amplification strategy with nanomaterials as a non-nanocatalyst; (A) the nanomaterials are formed with Fe3O4 and cerium dioxide (CeO2) decorated with gold nanoparticles (Fe3O4/CeO2@AuNPs) reproduced from. (a) Preparation procedure of Fe3O4/CeO2 @Au-S1, (b) signal amplification strategy and the detection principle for microRNA [146] with permission of the publisher; (B) biosensors using graphene oxide and DSN as amplification method from [147] reproduced with permission of the publisher.
Current sensitive electrochemical biosensors using the RedOx intercalating agent.
| MicroRNA | Intercalent Agent | Platform | Amplification of Signal Elements | Tech | Linear Range | LOD | Real-Samples Application | Ref |
|---|---|---|---|---|---|---|---|---|
| miRNA-155 | OB | GCE/GO/GNR | - | DPV | 2.0 fM–8.0 pM | 0.6 fM | Spiked human plasma | [ |
| miRNA-21 | TB | GCE/AuNPs-Ppy | - | DPV | 100 aM–1 nM | 78 aM | Spiked human serum. | [ |
| miRNA-196a | MB | AuE | DNA extension reaction | DPV | 0.05 fM–50 pM | 15 aM | Spiked plasma | [ |
| miRNA-486-5p | Thinonine | GCE/FeCN/AuNPs | FeCN | DPV | 1 fM–1000 pM | 8.53 fM | Human lung A549 cells | [ |
| miRNA-141 | RuHex | AuE | HP-AuNPs | DPV | 0–10 nM | 25.1 aM | Human breast cancer cells MDA-MB-231 | [ |
| miRNA-21 | RuHex | AuE | AuNPs enrichment by bridge DNA, | Chronocoulometry | 0.1fM–0.1nM | 68 aM | Serum samples from lung cancer patients | [ |
| miRNA-21 | RuHex | GCE/AuNPs@MoS2 | AuNPs@MoS2 | DPV | 10 fM–1 nM | 0.78 fM | Spiked human serum | [ |
| miRNA-21 | Molybdophosphate | AuE | HCR | SWV | 1 fM–1 nM | 0.78 fM | Spiked human serum | [ |
| miRNA-21 | CuNCs | AuE | HCR | DPSV | 10 pM–0.1 fM | 10 aM | Spiked blood sample | [ |
| miRNA-21 | Hemin | AuE | HCR | DPV | 15 fM–250 pM | 13.5 fM | Spiked human serum | [ |
| miRNA-199 a | AgNPs | AuE | C-rich loop DNA templates | DPV | 1.0 fM–0.1 nM | 0.64 fM | Spiked human serum | [ |
Abbreviations: GCE, glassy carbon electrode; MB, methylene blue; DPV, differential pulse voltammetry; AuE, gold electrode; FeCN, iron-embedded nitrogen-rich carbon nanotubes; AuNPs, gold nanoparticles; A549 cells, adenocarcinoma cells; GO, graphene oxide; GNR, gold nanorods; Ppy, polypyrrole; RuHex, hexaammineruthenium III chloride; HP-AuNPs, hairpin-modified gold nanoparticles; MDA-MB-231: human breast cancer cells; HCR, hybridization chain reaction; SWV, square wave voltammetry; CuNCs, copper nanoclosters; DPSV, differential pulse stripping voltammetry; AgNPs, silver nanoparticles; C-rich loop DNA templates, cytosine-rich loop DNA templates; TB, toluidine blue; OB, oracet blue.
Figure 14(A) Pricipale of electrochemical biosensors based on free RedOx indicator (a’) before and (b’) after hybridizition. (B) EIS and DPV response of the electrochemical biosensor based on free RedOx indicator (a’) before and (b’) after hybridization.
Figure 15Experimental principle of the biosensor (reproduced with permission from the publisher) [171].
Figure 16Scheme presenting the use of two free RedOx indicators reprinted from [180] with permission from (Anal. Chem.2017, 89, 12293--11298). Copyright (2017) American Chemical Society.
Current sensitive electrochemical biosensors using free RedOx indicator.
| MicroRNA | Free RedOx Indicator | Platform | Amplification Agent | Technique | Linear Range/LOD | LOD | Real-Samples Application | References |
|---|---|---|---|---|---|---|---|---|
| miRNA-21 | Fe(CN)63−/4- | AuE | biotin-FNPs | EIS | 0.1–250 fM | 0.1 fM | - | [ |
| miRNA-21 | Fe(CN)63−/4- | GCE | AuNPs | EIS | 1–1000 pM | 0.3 pM | Spiked serum sample | [ |
| miRNA-21 | Fe(CN)63−/4- | Magnetic GCE | DSN | EIS | - | 60 aM | Human serum from breast cancer patients | [ |
| miRNA-199a-5p | Fe(CN)63−/4- | GCE/GO/GNR | GO and GNR | EIS | 148 pM–15 fM | 4.5 fM | Spiked human blood serum | [ |
| miRNA-155 | Fe(CN)63−/4- | Pt wire/Ti3C2Tx@FePcQDs | Ti3C2Tx@FePcQDs | EIS | 0.01 fM–10 pM | 4.3 aM | Spiked human serum samples | [ |
| miRNA-21 | Fe(CN)63−/4- | AuE | HCR | EIS | 10 fM–50 pM | 4.63 fM | A549, HeLa, MCF-7, RAW 264.7, and HUVEC cancer cells | [ |
| miRNA-21 | Fe(CN)63−/4- | SPE/rGO-Au | - | DPV | 1 µM–1 pM | 1pM | Spiked artificial saliva | [ |
| miRNA-319a | Fe(CN)63−/4- | GCE/AuNPs | nuclease S1 | DPV | 1000–5 pM | 1.8 pM | - | [ |
| miRNA-21 | Fe(CN)63−/4- | FTO/NFG/AgNPs/PANI | - | DPV | 10 fM–10 μM | 0.2 fM | Spiked blood samples | [ |
| miRNA-21 | Fe(CN)63−/4- | FTO/CGO/Au-PtBNPs/SA | - | DPV | 1 fM–1 μM | 1 fM | spiked human serum | [ |
| miRNA-21 | Fe(CN)63−/4- | GCE/MWCNTs | TRNEAS | DPV | 0.1 fM–5 pM | 56.7 aM | MDA-MB-231, MCF-7, HeLa, and L02 cell | [ |
| hsa-miR-486-5p | Fe(CN)63−/4- | Laser induced graphene | - | DPV | 10 fM | - | [ | |
| miRNA-375 | Fe(CN)63−/4- | AuE | - | SWV | 10–30 fM | 11.7 aM | CaP | [ |
| miRNA | [Ru(NH3)6]3+/2+ | GCE/Ni PFNs | - | EIS | 0.1–2500 pM | 0.034 pM | A549 cancer cells | [ |
| let-7a | [Ru(NH3)6]3+/2+ | GCE/CNTs | CNT based solid-phase RCA | DPV | 1.2 fM | HeLa cells | [ | |
| miRNA-21 | Fe(CN)63−/4−/[Ru(NH3)6]3+/2+ | ITO | - | DPV | 0.1–1500 fM | 33 aM | HeLa, A549, MCF-7 cancer cells | [ |
Abbreviations: HCR, hybridization chain reaction; FTO, fluorine-doped tin oxide; NFG, nitrogen-doped functionalized graphene; AgNPs, silver nanoparticles; PANI, polyaniline; CGO, carboxylated graphene oxide; Au-PtBNPs, gold platinum bimetallic nanoparticles; SA, streptavidine; GCE, glassy carbon electrode; MWCNTs, multi-walled-carbone nanotube; AuE, gold electrode; MGCE, magnetic glassy carbon electrode; GO, graphene oxide; Fe(CN)63−/4, ferri/ferrocyanide; DPV, differential pulse voltammetry; MDA-MB-231, human breast cancer cell lines; MCF-7, human breast adenocarcinoma cell line; HeLa, human cervical cancer cell line; and L02 cell; SWV, square wave voltammetry; DSN, duplex-specific nuclease; EIS, electrochemical impedance spectroscopy; GNR, gold nanoroad; Pt wire/Ti3C2Tx@FePcQDs, platinium wire/iron phthalocyanine quantum dots; HUVEC, human umbilical vein endothelial; A549, non-small cell lung; RAW 264.7, mouse leukemia cells of monocyte-macrophage; biotin-FNPs, biotine-phenylalanine nanoparticles; Ni PFNs, nickel phosphate nanostructures; [Ru(NH3)6]3+/2+, hexaammineruthenium(III) chloride; TRNEAS, target-recycled non-enzymatic amplification strategy; ITO, indium tinoxide; PNT, peptide nanotube nanocomposite; biotin-FNPs, biotinylated phenylalanine nanoparticles; Au, gold; rGO, reduced graphene oxide; RCA, rolling-circle amplification.
Figure 17Distribution percentage of different microRNA strategies detection based on electrochemical biosensors.